U.S. flag An official website of the United States government
  1. Home
  2. Medical Devices
  3. Products and Medical Procedures
  4. Implants and Prosthetics
  5. Essure Permanent Birth Control
  1. Products and Medical Procedures

Essure Permanent Birth Control

Essure Permanent Birth Control

Bayer Has Stopped Selling and Distributing Essure in the United States

On December 31, 2018, Bayer stopped selling and distributing the Essure device in the United States. Health care providers can implant Essure up to one year from the date the device was purchased. Bayer will continue to implement the FDA's restriction on sale and distribution of Essure from April 2018, to ensure women are fully informed of the risks associated with the device.

Essure is a permanently implanted birth control device for women (female sterilization). Implantation of Essure does not require a surgical incision.

In the procedure, a health care provider places flexible inserts through the vagina and cervix and into the fallopian tubes – the tubes that carry the eggs from the ovaries to the uterus. Over a period of about three months, tissue forms around the inserts. The build-up of tissue creates a barrier that keeps sperm from reaching the eggs and prevents conception.

Essure is a permanent form of birth control and is not intended to be removed. Get information about Essure for patients.

On this page:


Benefits and Risks of Essure

Women are encouraged to discuss all available sterilization and birth control options and carefully consider the benefits and risks of each, with their health care provider before deciding on the method that is right for them.

The FDA continues to take concerns about Essure very seriously. As the FDA learned more from patients about the serious adverse events associated with this device, we took a series of important actions to better understand the benefits and risks, and to address patient safety concerns. Protecting patients by ensuring the safety and effectiveness of medical products on the U.S. market is an agency priority and the core of our consumer protection role. Learn more about the benefits and risks of Essure.

FDA's Recent Activities

May 15, 2019: As part of our continuing commitment to regularly communicate about Essure with patients and health care providers, the FDA updated the information on the FDA Activities: Essure webpage about medical device reports received in 2018. The FDA continues to post the latest information about the manufacturer’s postmarket surveillance study on the 522 study webpage.

December 2018: The FDA approved a revised postmarket surveillance ("522 study") plan that extends Bayer's mandatory follow up of women enrolled in the study from three years to five years. The FDA provided an update related to the ongoing postmarket review of Essure, including the status of the 522 study and information about device removal from medical device reports and an ongoing post-approval study.

April 2018:  The FDA restricted sale and distribution of Essure by requiring that the device only be sold to health care providers that share and sign the Bayer's Patient-Doctor Discussion Checklist in the Patient Information booklet with all women who choose to get Essure placed.

The FDA restricted the sale and distribution of Essure to health care providers who agree to review Bayer's Patient-Doctor Discussion Checklist [PDF] with patients, and give them the opportunity to sign it, before Essure implantation. The FDA approved this new safety measure to ensure that the device meets our standards for providing a reasonable assurance of safety and effectiveness.

Overview of the FDA's efforts to monitor the safety of Essure

Press Announcements on Essure

Additional Information